Market Place
Sourcing Support
Protara Therapeutics to Participate in Investor Conferences
19 Feb 2026 //
GLOBENEWSWIRE
Protara Therapeutics Discloses Inducement Grants Per Nasdaq LR
02 Feb 2026 //
GLOBENEWSWIRE
Protara Therapeutics at 44th J.P. Morgan Healthcare Conference
07 Jan 2026 //
GLOBENEWSWIRE
Protara Announces Proposed Public Offering
04 Dec 2025 //
GLOBENEWSWIRE
Protara Therapeutics To Review Phase 2 STARBORN-1 Trial Data
18 Nov 2025 //
GLOBENEWSWIRE
Protara Therapeutics Reveals Q3 2025 Financials & Business
10 Nov 2025 //
GLOBENEWSWIRE
Protara Therapeutics Discloses Inducement Grants Per Nasdaq LR
01 Oct 2025 //
GLOBENEWSWIRE
Protara Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
02 Sep 2025 //
GLOBENEWSWIRE
Protara Therapeutics to Present at Investor Conferences
27 Aug 2025 //
GLOBENEWSWIRE
Protara Reveals Q2 2025 Financial Results and Business Update
11 Aug 2025 //
GLOBENEWSWIRE
Protara Therapeutics Reports Inducement Grants Under Nasdaq
01 Jul 2025 //
GLOBENEWSWIRE
Protara Therapeutics Added to Russell 3000® Index
30 Jun 2025 //
GLOBENEWSWIRE
Protara Therapeutics Appoints William Conkling as CCO
02 Jun 2025 //
GLOBENEWSWIRE
Protara Therapeutics to Join Investor Conferences
13 May 2025 //
GLOBENEWSWIRE
Protara Therapeutics Reports Inducement Grants Under Nasdaq
01 May 2025 //
GLOBENEWSWIRE
Protara Presents THRIVE-1 Data On Choline Deficiency
19 Mar 2025 //
GLOBENEWSWIRE
Protara Therapeutic Announces Q4 & Full Year 2024 Financial Results
05 Mar 2025 //
GLOBENEWSWIRE
Protara Therapeutics To Present At TD Cowen Health Care Conference
26 Feb 2025 //
GLOBENEWSWIRE
Protara Therapeutic to Present at Oppenheimer Healthcare Conference
05 Feb 2025 //
GLOBENEWSWIRE
Protara Highlights Recent Updates and Anticipated 2025 Milestones
13 Jan 2025 //
GLOBENEWSWIRE
Protara Therapeutics to Present at Annual J.P. Morgan Conference
08 Jan 2025 //
GLOBENEWSWIRE
Protara Announces Proposed Public Offering
09 Dec 2024 //
GLOBENEWSWIRE
Protara Announces Pricing of $100 Million Public Offering
09 Dec 2024 //
GLOBENEWSWIRE
Protara Announces Q3 2024 Results & Business Update
12 Nov 2024 //
GLOBENEWSWIRE
Protara Therapeutics to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
Protara Therapeutics Reports Q2 2024 Results And Business Update
06 Aug 2024 //
GLOBENEWSWIRE
Protara Therapeutics Reports Inducement Grant Under Nasdaq Rule 5635(c)(4)
24 Jun 2024 //
GLOBENEWSWIRE
Protara To Present At Cowen Oncology Innovation Summit
21 May 2024 //
GLOBENEWSWIRE
Protara Q1 2024 Results, Business Update
02 May 2024 //
GLOBENEWSWIRE
Protara Announces Align with FDA on Reg Path Forward for IV Choline Chloride
05 Apr 2024 //
GLOBENEWSWIRE
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement
05 Apr 2024 //
GLOBENEWSWIRE
Protara Announces Fourth Quarter and Full Year 2023 Financial Results
13 Mar 2024 //
GLOBENEWSWIRE
Protara to Present at the TD Cowen 44th Annual Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
Protara Therapeutics to Participate in Upcoming Investor Conferences
31 Jan 2024 //
GLOBENEWSWIRE
Protara Therapeutics Announces Third Quarter 2023 Financial Results
03 Nov 2023 //
GLOBENEWSWIRE
Protara Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial
20 Sep 2023 //
GLOBENEWSWIRE
Protara to Present at H.C. Wainwright 25th Annual Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
Protara Announces Second Quarter 2023 Financial Results and Business Update
03 Aug 2023 //
GLOBENEWSWIRE
Protara Therapeutics Announces 1Q FYR 2023 and Business Update
04 May 2023 //
GLOBENEWSWIRE
Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Ph2
02 May 2023 //
GLOBENEWSWIRE
Protara Announces Fourth Quarter and Full Year 2022 Financial Results
08 Mar 2023 //
GLOBENEWSWIRE
Protara Therapeutics to Participate in Upcoming Investor Conferences
01 Mar 2023 //
GLOBENEWSWIRE
Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
02 Feb 2023 //
GLOBENEWSWIRE
Protara Announces Appointment of Patrick Fabbio as Chief Financial Officer
30 Jan 2023 //
GLOBENEWSWIRE
Protara Announces Trials Progress Poster Presentation for the ADVANCED-1 Trial
01 Dec 2022 //
GLOBENEWSWIRE
Protara Therapeutics Announces 3Q FYR and Business Overview
03 Nov 2022 //
GLOBENEWSWIRE
Protara Therapeutics Announces Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Protara Therapeutics Announces Departure of Chief Financial Officer
21 Jun 2022 //
GLOBENEWSWIRE
Protara Tx Announces Trials in Poster Presentation for ADVANCED-1 Trial in NMIBC
26 May 2022 //
GLOBENEWSWIRE
Protara Therapeutics to Present at H.C. Wainwright Global Investment Conference
17 May 2022 //
GLOBENEWSWIRE
Protara Therapeutics Presents Results from Retrospective Analysis of OK-432
12 May 2022 //
GLOBENEWSWIRE
Protara Therapeutics Announces First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Protara Tx Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002
24 Mar 2022 //
GLOBENEWSWIRE
Protara Tx says Q4 and FY 2021 Financial Results
09 Mar 2022 //
GLOBENEWSWIRE
Protara Therapeutics to Participate in Upcoming Investor Conferences
02 Mar 2022 //
GLOBENEWSWIRE
Protara Announces Q3 2021 Financial Results and Business Overview
04 Nov 2021 //
GLOBENEWSWIRE
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq
25 Oct 2021 //
GLOBENEWSWIRE
Protara Announces FDA Clearance of InG New Drug Application for TARA-002
12 Oct 2021 //
GLOBENEWSWIRE
Protara Therapeutics Announces FDA Clearance Of INDA For TARA-002
12 Oct 2021 //
BENZINGA
Protara to Present at Oppenheimer Fall Healthcare Life Sciences, MedTech Summit
17 Sep 2021 //
GLOBENEWSWIRE
